Olsalazine

Olsalazine is an orally active prodrug of 5-ASA (HY-15027) . Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic[1][2][3][4].

Product Specifications

CAS Number

[15722-48-2]

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/olsalazine.html

Purity

99.83

Solubility

DMSO : 20 mg/mL (ultrasonic)

Smiles

O=C(O)C1=C(O)C=CC(/N=N/C2=CC(C(O)=O)=C(O)C=C2)=C1

Molecular Formula

C14H10N2O6

Molecular Weight

302.24

Precautions

H315, H319

References & Citations

[1]Brown WA, et al. 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci. 2000 Aug;45 (8) :1578-84.|[2]Thapa D, et al. Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis. Int J Mol Sci. 2025 Aug 16;26 (16) :7913.|[3]Niu Y, et al. Olsalazine Sodium Increases Renal Urate Excretion by Modulating Urate Transporters in Hyperuricemic Animals. Biol Pharm Bull. 2020 Nov 1;43 (11) :1653-1659.|[4]Itoh S, et al. Olsalazine inhibits cell proliferation and DNA methylation in canine lymphoid tumor cell lines. Pol J Vet Sci. 2021 Dec;24 (4) :515-523.